Trevi Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger from Needham maintained a Buy rating on the stock and has a $22.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Serge Belanger has given his Buy rating due to a combination of factors related to Trevi Therapeutics’ strategic plans and potential. The company is gearing up for significant developments in 2026, with plans to initiate multiple clinical trials across various indications, including IPF cough, non-IPF ILDs, and RCC. These trials are expected to enhance the company’s pipeline and potentially lead to significant advancements in treatment options.
Belanger’s confidence in Trevi Therapeutics is further supported by the promising potential of Haduvio, the company’s key therapeutic candidate. Haduvio has shown the ability to address cough across different trials, suggesting a broad application in treating various cough-related conditions. This potential, combined with the company’s proactive approach to clinical development, underpins the Buy rating and the $22 price target set by Belanger.